Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  palonosetron hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A221301, NCI-2014-00446, U10CA031946, NCT02116530
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
Phase: Phase III
Type: Health services research, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011/366, NCT02135510
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CLOG1302, NCT02203253
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: sim-palonosetron, NCT01909856
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Gineolanzapina, NCT02290470
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Phase: Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 to less than 80
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ZYTOP1502, NCT02445872
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Phase: No phase specified
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: ALLG SC03, ACTRN12611001269921, NCT01843868
Start Over